SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Democratic gains in the midterms drove a sharp, volatile reaction in SPY, with traders debating whether the results threaten equities through potential AI regulation and policy shifts or ease uncertainty and bring a rebound. The community also focused on the indexs recovery after an initial selloff, with views split between buying the dip and expecting further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democrats projected midterm sweep has driven debate over whether a divided government could bring tighter AI and data-center rules, weighing on QQQs tech-heavy holdings. Traders are split between fearing further tech weakness and viewing the sharp selloff as an overreaction, with many pointing to a forceful rebound and possible short squeeze.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The projected Democratic takeover of Congress dominates discussion, with traders viewing the midterm results as a political setback for Trump and a negative backdrop for DJT; many posts are bearish and call for selling or shorting, while some argue broader-market gridlock could be favorable. The election-driven pressure on DJT is the central focus, rather than a company-specific development.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Traders are focused on claimed Democratic gains in the midterms, including a Texas shift, and fear that political scrutiny could threaten SpaceXs government contracts, Texas data-center expansion, or a proposed Tesla merger. Others argue those risks are overstated because of presidential veto powers and alternative data-center sites, while remaining bullish on SpaceXs technology and AI ambitions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Midterm-election uncertainty is driving debate over whether Democratic gains could bring tighter AI and data-center rules and weigh on chip stocks; others argue the buildout will continue, with AMDs strong results bolstering that view. The conversation also reflects a volatile rebound in semiconductors and anticipation of NVIDIAs upcoming earnings.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Traders are linking Teslas weakness to claims of Democratic election gains, speculating that a political shift could bring greater scrutiny of Musk and complicate a potential TeslaSpaceX merger. The reaction is mostly bearish, though some argue renewed EV incentives could help Tesla or that the political concerns are overblown.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is drawing attention amid sharp swings tied to midterm-election uncertainty, with traders debating whether potential data-center restrictions could slow AI spending; others argue memory demand and AI infrastructure remain strong. The rebound alongside semiconductors after AMDs strong results fueled dip-buying, while concerns about the memory cycle and continued volatility persist.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs stronger-than-expected results and upbeat outlook, driven by AI and data-center demand, are the main focus. Bulls see the growth outlook as a sign the AI trade remains strong, while skeptics question the valuation and cash flow and worry that election-related data-center restrictions could weigh on the rally.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Midterm-election results sparked a sharp, volatile swing in SOXL as traders worried a Democratic sweep could bring data-center restrictions and weigh on AI-related semiconductors. The community debated whether the selloff was an overreaction, while strong AMD and SMCI results helped fuel a subsequent chip-sector rebound.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Apples warning that memory prices are rising and expected to keep climbing has reinforced the bullish case for SanDisks storage business and helped fuel a rebound after a sharp selloff. Traders remain divided: some see durable AI and data-center demand supporting memory pricing, while others view the bounce as temporary amid concerns about cyclical demand and continued volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug 

Equity

Its late-stage trial targets 120 patients globally, with results aimed at pushing for a potential NDA filing in 2029.

Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today?

The company said VLX-1005 targets a high-risk heparin complication with limited treatment options.

Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) CFO Matthew Szot sold 9,933 shares of the company's stock in a transaction dated Monday, December 29th. The shares were sold at an average...

Why the underdog mindset could be your business superpower

You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. What does it take to go from refugee kid to Marine pilot, biotech CEO, and author? On this...

Cadrenal Therapeutics, Inc.  

Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million

The company said that the acquisition will significantly enhance its pipeline by adding novel assets in acute and chronic anticoagulation settings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Cadrenal is now planning a randomized, placebo-controlled study alongside standard anticoagulants.</li><li>The company's Phase 2 data showed over a 25% reduction in clotting, though the trial missed its primary endpoint on platelet recovery.</li><li>Cadrenal is also advancing its 12-LOX platform into areas like obesity and diabetes.</li></ul>Shares of Cadrenal Therapeutics, Inc. (CVKD) saw its retail sentiment peak to a record high late Sunday after the U.S. Food and Drug Administration (FDA) cleared the path for its blood clot drug CAD-1005 to advance into a Phase 3 trial for heparin-induced thrombocytopenia (HIT).<a href="https://stocktwits.com/symbol/CVKD">CVKD stock</a> jumped nearly 3% overnight heading into Monday. On Friday, shares fell 2% and extended losses by another 2% in extended trading.&nbsp;<h2 class="st-heading-2">CVKD Eyes Phase 3 After FDA Feedback</h2>The company said that the guidance came after its End-of-Phase 2 meeting, which was completed in March, covered protocol design, study population, dosing, background therapy, safety database, and the primary endpoint of new or worsening thrombotic events. Based on the feedback, Cadrenal will initiate a randomized, blinded, placebo-controlled Phase 3 trial evaluating CAD-1005 alongside standard anticoagulant therapy.“Building on our Phase 2 experience with CAD-1005 in HIT and now with FDA guidance for Phase 3, Cadrenal is positioned to pursue a pivotal trial for the first new therapy for HIT in more than two decades,” CEO Quang X. Pham said in a statement.&nbsp;&nbsp;In February, Cadrenal reported results from the trial, which showed over a 25% absolute reduction in thrombotic events in patients treated with CAD-1005 on top of standard anticoagulants, compared with placebo. The study did not meet its primary endpoint based on platelet count recovery, which the company said may not be an appropriate indicator for clinical benefit in HIT.Despite similar platelet recovery rates across both groups, fewer thrombotic events were observed in the CAD-1005 arm, with high event rates continuing in the placebo group. The company had earlier scheduled the End-of-Phase 2 meeting with the FDA in February and subsequently completed it in March, where it clarified a potential registrational pathway and began incorporating regulatory feedback into its Phase 3 protocol.<h2 class="st-heading-2">Cadrenal Targets 2029 NDA with Phase 3 Study</h2>Cadrenal’s Phase 3 study is expected to enroll around 120 patients across up to 50 clinical centers globally. Patients with suspected HIT will be randomized to receive CAD-1005 or placebo while continuing standard anticoagulant therapy and treated for up to 14 days during hospitalization.&nbsp;The primary endpoint will assess to see how often patients develop new blood clots, or if existing clots get worse, among those who are confirmed to have HIT, using a lab test called the Serotonin Release Assay, with at least one interim analysis planned. The company said the study is aimed at a potential New Drug Application submission in 2029.Cadrenal Expands Drug PipelineIn March, Cadrenal said it was expanding its pipeline of drugs that target the 12-lipoxygenase (12-LOX) pathway after adding more compounds to its portfolio, including some that can be taken orally. However, the company made clear that its focus remains on advancing CAD-1005 for HIT.However, the company said that early research suggests that blocking the 12-LOX pathway could have potential uses beyond HIT, including in conditions like obesity, type 2 diabetes and other inflammatory diseases. CAD-1005 is currently the only 12-LOX inhibitor currently in clinical-stage development and has received Orphan Drug and Fast Track designations from the FDA, along with orphan drug status from the European Medicines Agency.<h2 class="st-heading-2">How Do Retail Traders Feel About CVKD?</h2>On Stocktwits, retail sentiment for CVKD was ‘extremely bullish’ at a record high of 99/100 amid ‘extremely high’ message volume.CVKD stock has declined 62% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gme-stock-ebay-deal-etsy-alternative-retail-traders/cZQAAUBRe7W">GameStop–eBay Deal Buzz Sparks Retail Backlash, With Some Floating Etsy Instead&nbsp;</a>

 In this photo illustration, the Cadrenal Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cadrenal Therapeutics, Inc.

Republicans keep both chambers

Republicans keep the House, lose the Senate

Republicans keep the Senate, lose the House

Democrats win both chambers

Stocktwits

Stocktwits Polls

Click the link below to join Starlight ⬇️ 
 
Easily the best small-cap community I’ve found 🔥 
 
It’s completely free to join for now, but access is limited/12 
 
Watching $CVKD & $GLND <<

Juan

$CVKD I have only spend a couple of hours reading on this. None of this makes sense. Tecarfarin shows incredible promise. Onvoloxastat shows incredible promise. Have they been hiding from BP?

Bob marks

$CVKD commences a strategic review to explore licensing, sales, partnerships or other transactions to maximize company value.

jorge .miguel

$CVKD Been adding here slowly over the past few weeks.  100k shares starter position right now at 1.00/share avg.  Will double to 200k shares next week if stock is still around these levels.  They engaged Tungsten Advisors (same as $BOLT) about a month ago to look into strategic alternatives.  Most definitely going to be some sort of resolution here in the next 4-6 weeks imo.

$CVKD The company has executed a reverse stock split with 1 for 15 ratio in 2024.  Nasdaq’s $1.00 minimum bid price rule for continued listing make them to execute another RS?

applekitae@me.com

$CVKD  i got out on Dec 17, 2025 with 12% gain.  been advising to avoid ever since.  Whoever bought those direct offerings should have listened to me.  Like I said:

$CVKD  risk of dilution and reverse split, rising rates, bad season for stocks (until at least the midterms are over), then tax loss harvest season in Dec.   CVKD is asymmetric to the downside right now

$CVKD ; hope some good comes from this for the sake of the shareholders "Strategic process will consider potential asset sales, business combinations and other transactions to maximize portfolio value."

Feed

News

Sentiment

Fundamentals

Info

CVKD Cadrenal Therapeutics, Inc.

Fundamentals

Latest CVKD News